SFM
VIGL

Sphera Funds Management’s Vigil Neuroscience VIGL Stock Holding History

Sphera Funds Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,604,429
Closed -$2.86M – 131
2025
Q1 		$2.86M Buy
1,604,429
+102,000
+7% +$229K 0.66% 49
2024
Q4 		$2.55M Sell
1,502,429
-145,175
-9% -$429K 0.46% 70
2024
Q3 		$5.6M Sell
1,647,604
-44,562
-3% -$165K 0.89% 42
2024
Q2 		$6.77M Sell
1,692,166
-38,248
-2% -$131K 0.92% 35
2024
Q1 		$5.9M Buy
1,730,414
+1,195,294
+223% +$3.73M 0.83% 44
2023
Q4 		$1.81M Buy
+535,120
New +$2.75M 0.29% 75

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Sphera Funds Management's VIGL Position: Q2 2025 in Review

Sphera Funds Management sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 1,604,429 shares — an estimated $2.86M sold.

Sphera Funds Management first reported a position in VIGL in Q4 2023 and held it in 6 quarters. The position peaked at $6.77M in Q2 2024. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Sphera Funds Management reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 1,604,429 Vigil Neuroscience shares in Q2 2025, an estimated $2.86M.
  • Sphera Funds Management first reported a position in Vigil Neuroscience in Q4 2023 and held it in 6 quarters.
  • Sphera Funds Management's Vigil Neuroscience position peaked at $6.77M in Q2 2024.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.